Image 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg

Image 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg

<p>Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recentl...

Full description

Saved in:
Bibliographic Details
Main Author: Hu Feng (6641357) (author)
Other Authors: Shasha Bi (19675897) (author), Shanshan Sun (275585) (author), Hongbo Yang (267562) (author), Haoxing Zhou (19675900) (author), Jingjing Mao (175629) (author), Na Li (6550) (author), Fujun Yang (8151096) (author)
Published: 2024
Subjects:
Oncology and Carcinogenesis not elsewhere classified
endometrial cancer
HER2-low
ADCS
RC48
recurrent metastasis
complete response
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items